Plant Comparison
Mugwort vs Common coltsfoot
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Mugwort and Common coltsfoot: both belong to the Asteraceae family; they share 4 indicated uses (arthritis / joint pain, inflammation (general), insomnia / sleeplessness, …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Mugwort | Common coltsfoot | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 2/10 | Comparable evidence |
| Insomnia / sleeplessness | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Multiple undescribed and known sesquiterpenoids and triterpenoids isolated from the leaves, several with anti-inflammatory activity.
Volatile oil containing thujone and other monoterpenes; thujone content is the basis of the caution on prolonged internal use.
Antioxidant and anti-inflammatory flavonoid and coumarin constituents.
Hepatotoxic constituents that are the central safety concern for this plant; regulatory limits and PA-controlled/PA-reduced products exist specifically because of these compounds.
Demulcent polysaccharide contributing to the traditional soothing action on irritated airways.
Pharmacological Actions
Artemisia vulgaris (mugwort) extracts inhibit BCR/ABL and induce apoptosis, ferroptosis and necroptosis in chronic myeloid leukaemia and breast cancer cells (preclinical).
Traditional & Indicated Uses
inferred from anti-inflammatory action
Artemisia vulgaris (mugwort) extracts inhibit BCR/ABL and induce apoptosis in chronic myeloid leukaemia cells (including imatinib-resistant), and trigger tumour-selective ferroptosis/necroptosis in breast cancer and leukaemia cells via lysosomal Ca2+ signalling (preclinical).
inferred from digestive action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from sedative action
inferred from antispasmodic action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from sedative action
Safety, Cautions & Contraindications
Contains thujone; avoid high doses or prolonged use. Contraindicated in pregnancy (uterine stimulant and abortifacient). May cause allergic reactions in individuals sensitive to the Asteraceae family. Avoid in epilepsy. Not recommended for children.
Duke (2002) rates mugwort as + (use with caution) and notes abortifacient (score 1), emmenagogue, aperitif (score 1), and insecticide activities. Duke clearly flags mugwort as contraindicated in pregnancy due to well-documented abortifacient and uterotonic properties. Traditional use has been as a digestive bitter, and the plant contains volatile oils, sesquiterpene lactones, and flavonoids. Duke notes that the plant may cause allergic reactions in individuals sensitive to Asteraceae and warns against long-term use due to potential neurotoxicity from thujone-containing essential oil (Duke, 2002).
Safety notes (contraindications, interactions, pregnancy/lactation notes, adverse effects, dose-duration cautions) Important: Coltsfoot naturally contains pyrrolizidine alkaloids (PAs)—plant chemicals that can damage the liver and may increase cancer risk with enough exposure (EMA, 2021; Kopp et al., 2020).
Because of this, European regulators set very strict limits for PA exposure from herbal products (EMA, 2021).
Many safety-focused herbal references recommend avoiding homemade/internal coltsfoot use, unless the product is specifically made to be PA-controlled / PA-reduced (EMA, 2021).
Avoid internal use if you are pregnant or breastfeeding, have liver disease, or for children—these groups are treated as “sensitive” in PA risk guidance (EMA, 2021).
Medication caution: if you take medicines that stress the liver (some prescription drugs can), it’s extra important to avoid unregulated PA exposure (general PA risk logic; consult a clinician) (EMA, 2021).
Topical use may still carry PA considerations; EMA discusses limits and recommends use only on intact skin for PA-containing products (EMA, 2021).
Duke (2002) provides clinical support (score 2) for coltsfoot's anti-inflammatory and expectorant effects, explaining its traditional use in bronchitis and coughs. However, the plant contains hepatotoxic pyrrolizidine alkaloids (PAs), and Duke notes a carcinogenic score (1) — a critical safety concern. Commission E has placed restrictions on coltsfoot use, recommending maximum internal use of 4–6 weeks per year and avoiding use in pregnancy, lactation, and in children under 12. Duke rates its overall safety as low (+) and emphasizes that preparations free of PAs are preferred (Duke, 2002).
External Ids
Botanical Description
Tall, aromatic perennial herb with deeply lobed, dark green leaves that are distinctively silvery-white and woolly beneath. Small, dull reddish-brown to yellowish flower heads are borne in dense, branched, leafy spikes. The reddish-brown, ridged stems and the leaf's contrasting silver underside are characteristic field marks.[3]
Low perennial herb notable for flowering before its leaves appear: solitary, bright yellow, dandelion-like flower heads emerge on scaly pinkish stalks in very early spring, followed later by large, hoof-shaped (heart-shaped with angular teeth), white-woolly-backed leaves arising directly from the creeping rhizome.[11]
Habitat
A common plant of waste ground, roadsides, hedgerows and riverbanks; native to Europe, Asia and North Africa and widely naturalised in North America.[3]
Grows on disturbed, damp or clay-rich waste ground, riverbanks, railway embankments and bare soil; native to Europe, North Africa and temperate Asia and naturalised in North America.[11]
Harvesting
The flowering aerial parts (leaf and stem) are cut in summer as flowering begins and dried in a warm, shaded, airy place; the root can be dug in autumn.[3]
Flowers are gathered in very early spring before the leaves appear; leaves are gathered later in the season once expanded. Given the plant's pyrrolizidine alkaloid content, harvesting from a positively confirmed patch (not a look-alike) and preferring PA-tested commercial material for internal use is strongly advised.[2]
Traditional Uses
Mugwort is a widely used traditional bitter digestive tonic and calming nervine, and has a long reputation as an emmenagogue for menstrual complaints (reflected in its traditional use to bring on delayed menstruation, which is also why it is contraindicated in pregnancy). It has also been burned as 'moxa' in East Asian moxibustion and used as an insect repellent ('sailor's tobacco').[3]
Coltsfoot has an ancient European and Chinese tradition, reflected in its Latin name (tussis = cough), as an expectorant and demulcent remedy for coughs, bronchitis and irritated airways; because of its pyrrolizidine alkaloid content, contemporary use is restricted to short courses of PA-controlled preparations under regulatory limits (see contraindications).[1, 2, 12]
Preparations
Commercially prepared, pyrrolizidine-alkaloid-tested extract or syrup, the only form recommended for internal use given the plant's natural PA content.
Dried flower or leaf infused in hot water; traditional but subject to strict duration/PA-content limits under EU herbal regulation.
Dosage
Health Canada's NNHPD monograph gives 0.2-2.4 g of dried herb top, 3 times per day, for adults 18 years and older, with infusion and decoction among the accepted methods of preparation. Educational reference only, not a prescription.
EU regulatory guidance restricts internal use to PA-controlled preparations. The EMA public statement on unsaturated pyrrolizidine alkaloids records a maximum daily intake for internal use of 1 microgram of PAs for at most 6 weeks per year, or 0.1 microgram per day with no duration limit; for cutaneous use the limits are 100 micrograms for at most 6 weeks per year, or 10 micrograms without a duration limit. Not for use in pregnancy, breastfeeding, or children. Note that these are limits on PA intake, not a herb dose — no EMA monograph exists for Tussilago farfara, so there is no official posology for the herb itself. Educational reference only, not a prescription — consult a qualified practitioner and prefer tested commercial products.
References
Drug Class Interactions
Not documented
Lookalikes Review
Dangerous Lookalikes
References & Sources
- Liu, T., Chen, X., Hu, Y., Li, M., Wu, Y. et al (2022) 'Sesquiterpenoids and triterpenoids with anti-inflammatory effects from Artemisia vulgaris L', Phytochemistry, 204, pp. 113428. doi:10.1016/j.phytochem.2022.113428 Preclinical
https://doi.org/10.1016/j.phytochem.2022.113428 - Trinh, P.T.N., Truc, N.C., Danh, T.T., Trang, N.T.T., Le Hang, D.T. et al (2024) 'A study on the antioxidant, anti-inflammatory, and xanthine oxidase inhibitory activity of the Artemisia vulgaris L. extract and its fractions', Journal of Ethnopharmacology, 334, pp. 118519. doi:10.1016/j.jep.2024.118519 Preclinical
https://doi.org/10.1016/j.jep.2024.118519 - Abiri, R., Silva, A.L.M., de Mesquita, L.S.S., de Mesquita, J.W.C., Atabaki, N. et al (2018) 'Towards a better understanding of Artemisia vulgaris: Botany, phytochemistry, pharmacological and biotechnological potential', Food Research International, 109, pp. 403-415. doi:10.1016/j.foodres.2018.03.072 Traditional / reference
https://doi.org/10.1016/j.foodres.2018.03.072 - Ekiert, H., Pajor, J., Klin, P., Rzepiela, A., Slesak, H. and Szopa, A (2020) 'Significance of Artemisia vulgaris L. (Common Mugwort) in the History of Medicine and Its Possible Contemporary Applications Substantiated by Phytochemical and Pharmacological Studies', Molecules, 25(19), pp. 4415. doi:10.3390/molecules25194415 Meta-analysis / review
https://doi.org/10.3390/molecules25194415 - Soon, L., Ng, P.Q., Chellian, J., Madheswaran, T., Panneerselvam, J., Gupta, G., Nammi, S., Hansbro, N.G., Hsu, A., Dureja, H., Mehta, M., Satija, S., Hansbro, P.M., Collet, T. and Chellappan, D.K (2019) 'Therapeutic potential of Artemisia vulgaris: An insight into underlying immunological mechanisms', Journal of Environmental Pathology, Toxicology and Oncology, 38(3), pp. 205-216. doi:10.1615/JEnvironPatholToxicolOncol.2019029397 Meta-analysis / review
https://doi.org/10.1615/JEnvironPatholToxicolOncol.2019029397 - Xiao, J., Liu, P., Hu, Y., Liu, T., Guo, Y., Sun, P., Zheng, J., Ren, Z. and Wang, Y (2023) 'Antiviral activities of Artemisia vulgaris L. extract against herpes simplex virus', Chinese Medicine, 18(1), pp. 21. doi:10.1186/s13020-023-00711-1 Preclinical
https://doi.org/10.1186/s13020-023-00711-1 - Singh, N.B., Devi, M.L., Biona, T., Sharma, N., Das, S., Chakravorty, J., Mukherjee, P.K. and Rajashekar, Y (2023) 'Phytochemical Composition and Antimicrobial Activity of Essential Oil from the Leaves of Artemisia vulgaris L', Molecules, 28(5), pp. 2279. doi:10.3390/molecules28052279 Preclinical
https://doi.org/10.3390/molecules28052279 - Judzentiene, A. and Budiene, J (2018) 'Chemical Polymorphism of Essential Oils of Artemisia vulgaris Growing Wild in Lithuania', Chemistry & Biodiversity, 15(2), pp. e1700257. doi:10.1002/cbdv.201700257 Preclinical
https://doi.org/10.1002/cbdv.201700257 - Hanh, T.T.H., Vinh, L.B., Cuong, N.X. and Quang, T.H (2022) 'Two new eudesmane sesquiterpene glucosides from the aerial parts of Artemisia vulgaris', Natural Product Research, 37(9), pp. 1544-1549. doi:10.1080/14786419.2022.2025591 Preclinical
https://doi.org/10.1080/14786419.2022.2025591 - Zamarioli, L.D.S., Santos, M.R.M., Erustes, A.G., Meccatti, V.M., Pereira, T.C., Smaili, S.S., Marcucci, M.C., Oliveira, C.R., Pereira, G.J.S. and Bincoletto, C (2023) 'Artemisia vulgaris Induces Tumor-Selective Ferroptosis and Necroptosis via Lysosomal Ca2+ Signaling', Chinese Journal of Integrative Medicine, 30(6), pp. 525-533. doi:10.1007/s11655-023-3712-2 Preclinical
https://doi.org/10.1007/s11655-023-3712-2 - Chi, H.T. and Ly, B.T.K (2022) 'Artemisia vulgaris inhibits BCR/ABL and promotes apoptosis in chronic myeloid leukemia cells', Biomedical Reports, 17(6), pp. 92. doi:10.3892/br.2022.1575 Preclinical
https://doi.org/10.3892/br.2022.1575 - Tiwari, R.K., Ahmad, A., Khan, A.F., Al-Keridis, L.A., Saeed, M., Alshammari, N., Alabdallah, N.M., Ansari, I.A. and Mujeeb, F (2023) 'Ethanolic Extract of Artemisia vulgaris Leaf Promotes Apoptotic Cell Death in Non-Small-Cell Lung Carcinoma A549 Cells through Inhibition of the Wnt Signaling Pathway', Metabolites, 13(4), pp. 480. doi:10.3390/metabo13040480 Preclinical
https://doi.org/10.3390/metabo13040480 - Health Canada, Natural and Non-prescription Health Products Directorate (2026) 'Natural Health Product Monograph: Mugwort - Artemisia vulgaris'. Available at: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_mugwort_english.pdf Traditional / reference
https://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_mugwort_english.pdf - Becker, H (1986) 'Botany of European Artemisia species', pp. 1--24. Traditional / reference
https://scholar.google.com/scholar?q=Botany%20of%20European%20Artemisia%20species - Grieve, M (1931) 'A Modern Herbal'. Traditional / reference
https://scholar.google.com/scholar?q=A%20Modern%20Herbal - Kung, H.J. and Ko, W.C (2002) 'Pharmacological studies of Artemisia vulgaris', 13(2), pp. 99--108. Traditional / reference
https://scholar.google.com/scholar?q=Pharmacological%20studies%20of%20Artemisia%20vulgaris - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003 - Totally Wild UK 'Mugwort (Artemisia vulgaris) Identification'. Available at: https://totallywilduk.co.uk/2021/04/13/identify-mugwort/ Traditional / reference
https://totallywilduk.co.uk/2021/04/13/identify-mugwort/ - Stetzenbach, M. and Schnorbus, B. and Sagoschen, I. and Bleser, W. and Legner, D. and Sturer, A (2017) 'Acute Monkshood Intoxication Requiring Acute Resuscitation', Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie, 52(9), pp. 641-644. doi:10.1055/s-0043-106283 Clinical study
https://doi.org/10.1055/s-0043-106283
- Ahmad, I., Kudaibergenova, B., Ahmad, M. and others (2025) 'Coltsfoot (Tussilago farfara L.; Asteraceae): modern methods of extraction, phytochemistry, nanoparticles synthesis, ethnopharmacology, and biological activities', Natural Product Research, pp. 1-20. doi:10.1080/14786419.2025.2548616 Traditional / reference
https://doi.org/10.1080/14786419.2025.2548616 - Chen, S., Dong, L., Quan, H., Zhou, X. and others (2020) 'A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)', Journal of Ethnopharmacology, 267, pp. 113478. doi:10.1016/j.jep.2020.113478 Traditional / reference
https://doi.org/10.1016/j.jep.2020.113478 - Feng, J., Zhang, Y., Qin, X., Gao, T. and others (2022) 'Novel Quinic Acid Glycerates from Tussilago farfara Inhibit Polypeptide GalNAc-Transferase', ChemBioChem, 23(3), pp. e202100539. doi:10.1002/cbic.202100539 Preclinical
https://doi.org/10.1002/cbic.202100539 - Zhao, J., Evangelopoulos, D., Bhakta, S., Gray, A.I. and Seidel, V (2014) 'Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents', Journal of Ethnopharmacology, 155(1), pp. 796-800. doi:10.1016/j.jep.2014.06.034 Preclinical
https://doi.org/10.1016/j.jep.2014.06.034 - Avila, C., Breakspear, I., Hawrelak, J., Salmond, S. and Evans, S (2020) 'A systematic review and quality assessment of case reports of adverse events for borage (Borago officinalis), coltsfoot (Tussilago farfara) and comfrey (Symphytum officinale)', Fitoterapia, 142, pp. 104519. doi:10.1016/j.fitote.2020.104519 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2020.104519 - Lee, J., Park, S., Kim, M.J., Kwon, S.J. and others (2019) 'Sesquiterpenoids from Tussilago farfara Flower Bud Extract for the Eco-Friendly Synthesis of Silver and Gold Nanoparticles Possessing Antibacterial and Anticancer Activities', Nanomaterials (Basel), 9(6), pp. 819. doi:10.3390/nano9060819 Preclinical
https://doi.org/10.3390/nano9060819 - Bota, V.B., Neamtu, A.A., Olah, N.K., Chiselita, O. and others (2022) 'A Comparative Analysis of the Anatomy, Phenolic Profile, and Antioxidant Capacity of Tussilago farfara L. Vegetative Organs', Plants (Basel), 11(13), pp. 1663. doi:10.3390/plants11131663 Preclinical
https://doi.org/10.3390/plants11131663 - Boucher, M.A., Cote, H., Pichette, A., Ripoll, L. and Legault, J (2020) 'Chemical composition and antibacterial activity of Tussilago farfara (L.) essential oil from Quebec, Canada', Natural Product Research, 34(4), pp. 545-548. doi:10.1080/14786419.2018.1489384 Preclinical
https://doi.org/10.1080/14786419.2018.1489384 - Li, Z.Y., Zhang, J., Zhang, Y.B., Yang, X.W. and others (2022) 'Polyhydroxylated eudesmane sesquiterpenoids and sesquiterpenoid glucoside from the flower buds of Tussilago farfara', Chinese Journal of Natural Medicines, 20(4), pp. 301-308. doi:10.1016/S1875-5364(21)60120-6 Preclinical
https://doi.org/10.1016/S1875-5364(21)60120-6 - Jang, H., Lee, J.W., Lee, C., Jin, Q. and others (2016) 'Sesquiterpenoids from Tussilago farfara inhibit LPS-induced nitric oxide production in macrophage RAW 264.7 cells', Archives of Pharmacal Research, 39(1), pp. 127-132. doi:10.1007/s12272-015-0667-7 Preclinical
https://doi.org/10.1007/s12272-015-0667-7 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Westendorf, J., Czok, G., Marquardt, R., Nausner, M., Krauer, B. and Paul, H.L (1988) 'Pyrrolizidine alkaloid content of Tussilago farfara plants from different regions and preparations', pp. 903--909. Traditional / reference
https://scholar.google.com/scholar?q=Pyrrolizidine%20alkaloid%20content%20of%20Tussilago%20farfara%20plants%20from%20different%20regions%20and%20preparations - European Medicines Agency (HMPC) (2021) 'Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs), including recommendations regarding contamination of herbal medicinal products with PAs, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Sperl, W. and Stuppner, H. and Gassner, I. and Judmaier, W. and Dietze, O. and Vogel, W (1995) 'Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea', European Journal of Pediatrics, 154(2), pp. 112-6. doi:10.1007/BF01991912 Clinical study
https://doi.org/10.1007/BF01991912
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.